innosferaНаука и инновацииScience and Innovations1818-98572412-9372Издательский дом «Белорусская наука»10.29235/1818-9857-2022-11-78-83innosfera-157Research ArticleДИССЕРТАЦИОННЫЕ ИССЛЕДОВАНИЯDISSERTATION RESEARCHНаночастицы в биологии и медицинеNanoparticles in biology and medicineСтановаяА.StanovayaA.

научный сотрудник лаборатории нанобиотехнологий, аспирант

alesiastanovaya@gmail.comТереховаМ.TerekhovaM.

младший научный сотрудник лаборатории нанобиотехнологий, аспирант

maryterekhova@tut.byАбашкинВ.AbashkinV.

научный сотрудник лаборатории нанобиотехнологий

viktar.abashkin@gmail.comОдабашиМ.OdabashiM.

заведующий кафедрой химии факультета искусства и науки, доктор химических наук, профессор

modabasi@aksaray.edu.trЩербинД.ShcherbinD.

заведующий лабораторией нанобиотехнологий, докторбиологических наук, доцент

shcharbin@lab.ibp.org.byИнститут биофизики и клеточной инженерии НАН БеларусиBelarusУниверситет АксарайTurkey2022141220220117883Copyright © Издательский дом «Белорусская наука», 20222022Издательский дом «Белорусская наука»Издательский дом «Белорусская наука»https://innosfera.belnauka.by/jour/about/submissions#copyrightNoticehttps://innosfera.belnauka.by/jour/article/view/157

Среди возможностей применения нанотехнологий в биологии и медицине особое место занимает использование наночастиц для адресной доставки лекарственных препаратов и транспорта нуклеиновых кислот в опухолевые клетки. Среди преимуществ такого подхода – уменьшение побочного действия химиотерапевтических препаратов на организм. В данном обзоре приведены краткая характеристика наночастиц, используемых в медицине, механизмы транспортировки лекарств с их помощью, а также представлены исследования в этой области, проводимые в Институте биофизики и клеточной инженерии НАН Беларуси.

The authors give characteristics of nanoparticles used in medicine and biology, consider the mechanisms of drug transport with their help, as well as research conducted at the Institute of Biophysics and Cell Engineering of the National Academy of Sciences of Belarus in this area.

наночастицынанотехнологиисвойства наночастицтранспорт наночастицРабота поддержана Государственным комитетом по науке и технологиям Республики Беларусь и Белорусским республиканским фондом фундаментальных исследований, гранты Б21КОРГ-001, Б21АРМГ-002, Б22УЗБ-003, Б21ТЮБ-001, Б21РМ-045, Б21M-001ReferencesAn Overview of the Applications of Nanomaterials and Nanodevices in the Food Industry / M. Shafiq [et al.] // Foods. 2020. Vol. 9, №2. P. 148.An Overview of the Applications of Nanomaterials and Nanodevices in the Food Industry / M. Shafiq [et al.] // Foods. 2020. Vol. 9, №2. P. 148.E. Pérez-Herrero. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy / E. Pérez-Herrero, A. Fernández-Medarde // Eur. J. Pharm. Biopharm. 2015. Vol. 93. P. 52–79.E. Pérez-Herrero. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy / E. Pérez-Herrero, A. Fernández-Medarde // Eur. J. Pharm. Biopharm. 2015. Vol. 93. P. 52–79.D. M. Moss. Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling / D. M. Moss, M. Siccardi // Br. J. Pharmacol. 2014. Vol. 171. №17. P. 3963–3979.D. M. Moss. Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling / D. M. Moss, M. Siccardi // Br. J. Pharmacol. 2014. Vol. 171. №17. P. 3963–3979.E. Samaridou. Lipid nanoparticles for nucleic acid delivery: Current perspectives / E. Samaridou, J. Heyes, P. Lutwyche // Adv. Drug. Deliv. Rev. 2020. Vol. 154–155. P. 37–63.E. Samaridou. Lipid nanoparticles for nucleic acid delivery: Current perspectives / E. Samaridou, J. Heyes, P. Lutwyche // Adv. Drug. Deliv. Rev. 2020. Vol. 154–155. P. 37–63.Chemistry of Lipid Nanoparticles for RNA Delivery / Y. Eygeris [et al.] // Acc. Chem. Res. 2022. Vol. 55. №1. P. 2–12.Chemistry of Lipid Nanoparticles for RNA Delivery / Y. Eygeris [et al.] // Acc. Chem. Res. 2022. Vol. 55. №1. P. 2–12.D. A. Tomalia. In quest of a systematic framework for unifying and defining nanoscience / D. A. Tomalia // J. Nanopart. Res. 2009. Vol. 11. №6. P. 1251–1310.D. A. Tomalia. In quest of a systematic framework for unifying and defining nanoscience / D. A. Tomalia // J. Nanopart. Res. 2009. Vol. 11. №6. P. 1251–1310.How to study dendrimers and dendriplexes III. Biodistribution, pharmacokinetics and toxicity in vivo / D. Shcharbin [et al.] // J. Control. Release. 2014. Vol. 181, №1. P. 40–52.How to study dendrimers and dendriplexes III. Biodistribution, pharmacokinetics and toxicity in vivo / D. Shcharbin [et al.] // J. Control. Release. 2014. Vol. 181, №1. P. 40–52.Therapeutic nanoparticles for drug delivery in cancer / K. Cho [et al.] // Clin. Cancer Res. 2008. Vol. 14. №5. P. 1310–1316.Therapeutic nanoparticles for drug delivery in cancer / K. Cho [et al.] // Clin. Cancer Res. 2008. Vol. 14. №5. P. 1310–1316.M. Wang. Targeting nanoparticles to cancer / M. Wang, M. Thanou // Pharmacol. Res. 2010. Vol. 62. №2. P. 90–99.M. Wang. Targeting nanoparticles to cancer / M. Wang, M. Thanou // Pharmacol. Res. 2010. Vol. 62. №2. P. 90–99.M. Rippe. Design of soft nanocarriers combining hyaluronic acid with another functional polymer for cancer therapy and other biomedical applications / M. Rippe, V. Cosenza, R. Auzély-Velty // Pharmaceutics. 2019. Vol. 11, №7. P. 338.M. Rippe. Design of soft nanocarriers combining hyaluronic acid with another functional polymer for cancer therapy and other biomedical applications / M. Rippe, V. Cosenza, R. Auzély-Velty // Pharmaceutics. 2019. Vol. 11, №7. P. 338.Carbon Nanotubes in Cancer Therapy and Drug Delivery / A. Elhissi [et al.] // Emerging Nanotechnologies in Dentistry. 2012. Vol. 2012. P. 347–363.Carbon Nanotubes in Cancer Therapy and Drug Delivery / A. Elhissi [et al.] // Emerging Nanotechnologies in Dentistry. 2012. Vol. 2012. P. 347–363.Nanomedicine therapeutic approaches to overcome cancer drug resistance / J. L. Markman [et al.] // Adv. Drug Deliv. Rev. 2013. Vol. 65. №13–14. P. 1866–1879.Nanomedicine therapeutic approaches to overcome cancer drug resistance / J. L. Markman [et al.] // Adv. Drug Deliv. Rev. 2013. Vol. 65. №13–14. P. 1866–1879.Nanomaterials in combating cancer: Therapeutic applications and developments / S. Nazir [et al.] // Nanomedicine. 2014. Vol. 10. №1. P. 19–34.Nanomaterials in combating cancer: Therapeutic applications and developments / S. Nazir [et al.] // Nanomedicine. 2014. Vol. 10. №1. P. 19–34.R. K. Jain. Delivering nanomedicine to solid tumors / R. K. Jain, T. Stylianopoulos // Nat. Rev. Clin. Oncol. 2010. Vol. 7. №11. P. 653–664.R. K. Jain. Delivering nanomedicine to solid tumors / R. K. Jain, T. Stylianopoulos // Nat. Rev. Clin. Oncol. 2010. Vol. 7. №11. P. 653–664.F. Danhier. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery / F. Danhier, O. Feron, V. Préat // J. Control. Release. 2010. Vol. 148. №2. P. 135–146.F. Danhier. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery / F. Danhier, O. Feron, V. Préat // J. Control. Release. 2010. Vol. 148. №2. P. 135–146.Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress / T. Lammers [et al.] // J. Control. Release. 2012. Vol. 161. №2. P. 175–187.Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress / T. Lammers [et al.] // J. Control. Release. 2012. Vol. 161. №2. P. 175–187.E. Blanco. Principles of nanoparticle design for overcoming biological barriers to drug delivery / E. Blanco, H. Shen, M. Ferrari // Nat. Biotechnol. 2015. Vol. 33. №9. P. 941–951.E. Blanco. Principles of nanoparticle design for overcoming biological barriers to drug delivery / E. Blanco, H. Shen, M. Ferrari // Nat. Biotechnol. 2015. Vol. 33. №9. P. 941–951.Y.H. Bae. Targeted drug delivery to tumors: Myths, reality and possibility / Y. H. Bae, K. Park // J. Control. Release. 2011. Vol. 153. №3. P. 198–205.Y.H. Bae. Targeted drug delivery to tumors: Myths, reality and possibility / Y. H. Bae, K. Park // J. Control. Release. 2011. Vol. 153. №3. P. 198–205.

The authors declare that there are no conflicts of interest present.